Menu
News
Recent news
Santersus AG, a privately held therapeutic apheresis company, announced today that their medical device product, NucleoCapture, has been granted designation as a Breakthrough Device by The Center for Devices and Radiological Health (CDRH) of the US Food and Drug Administration (FDA). The indication cited in the breakthrough designation is as an adjunctive treatment to antibiotics in patients with sepsis.
December 12, 2022
Hence, this important study reveals how microbial exploitation of phagocytic receptors is linked to triggering of sepsis and the immune cell mediated reduction in neutrophil life span. The explored pathway creates a novel therapeutic opportunity for NucleoCapture, which would eliminate circulating chromatin and aid with immune dysfunction without compromising the defensive function of neutrophils.
September 30, 2021
Santersus AG announces the successful completion of their first in human clinical trials relating to Sepsis and COVID-19.
This important publication reveals the profound impact of cell-free DNA clearance and its involvement in the survival of patients who suffer from severe SARS-CoV-2 infection. This obviously presents a novel therapeutic opportunity for our technology, NucleoCapture, which allows for selective removal of NETs from blood without compromising the defensive function of neutrophils.